Analyst Ratings for Blueprint Medicines (BPMC)
Overall Rating:
NEUTRAL
Rating Trend:
=
Avg. $ Target:
N/A
Rating Score: 3.8 / 10
Percentile Rank: 36%
Rating Score: 3.8 / 10
Percentile Rank: 36%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/17/2025 | Wells Fargo | Derek Archila | Downgrade | Equal Weight (Overweight) |
129.00 (N/A) |
128.25 (129.46) |
0.94% | Details |
| 6/4/2025 | Citi | David Lebowitz | Upgrade | Neutral (N/A) |
129.00 (83.00) |
127.79 (129.46) |
1.31% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
